Panion's epilepsy drug candidate shows positive initial results in a long-term study by CombiGene

Panion Animal Health AB develops a new epilepsy medicine for dogs based on CombiGene's drug vector CG01. Initial results from CombiGene's long-term study in rats was released yesterday in a message, which is highly relevant for Panion's development of the product for epilepsy in dogs.

Professor Merab Kokaia from Lund University, who has lead the study, expresses his joy over the results.

http://combigene.com/2/wp-content/uploads/2017/12/ CombiGene_PM_20171206_long-term_study.pdf

He explains that the study analyses three different parameters related to the epileptic brain.

  • Magnetic Resonance scanning (MR) evaluates the magnitude of damage in the brain;

  • Electro-encephalography (Video-EEG) observes the epileptic attacks and measures the electric activity of the brain during a seizure;

  • Histological analysis of the brain tissue that evaluates changes in the epileptic brain tissue compared to normal tissue and measures the expression of CG01 in the tissue. 

This film presents the study:
https://vimeo.com/245921380 (English subtitles).

"We congratulate CombiGene with the excellent performance of this important in-vivo study, which confirms our trust in the scientific robustness of the future treatment" says Anja Holm, CEO of Panion.. 

DECEMBER 7 2017

For further information, please contact:
Anja E. H. Holm, CEO | + 45-22 94 66 00
anja.holm@panion-animalhealth.com 

Developing animal health - In Panion, we want to improve the quality of life for animals suffering from chronic diseases. We are convinced that gene therapy has promising prospects. Our aim is to develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, based on CombiGene AB's technology and platform. Panion Animal Health AB is listed at AktieTorget. 

Nerladdningsbara filer

DRA contract ends & New advisory board member

Panion Animal Health AB's Director Regulatory Affairs, Niels-Erik Manniche, has decided to leave the company.


Panion enters into SEK 9,5 million financing and receives SEK 3 million in first tranche financing

Panion Animal Health AB (the "Company") has entered into a financing agreement with New York based Yorkville Advisors Global ("Yorkville") as the investment manager and on behalf of one or more of its investment funds has agreed to purchase up to SEK 9,000,000 of Convertible Notes of Panion Animal Health AB. In addition, Panion has entered into a financing agreement with Dividend Sweden who has agreed to purchase SEK 500,000 of convertible Notes of Panion Animal Health AB.


Panion's epilepsy product candidate for gene therapy in the dog: FDA has established an Investigational New Animal Drug (INAD) file.

Panion Animal Health AB ("Panion") has in Q4-17 requested the FDA to open an Investigational New Animal Drug application file to carry out the development of our new product for use in the dog. Panion plans to develop and gain approval for the use of CG-01-canine, a recombinant adeno-associated virus vector expressing neuropeptide Y and receptor peptide Y2 to treat drug refractory idiopathic epilepsy in the dog via intracranial injection.


New CFO in Panion, Sofia Josephson

Panion Animal Health AB has had a very satisfactory cooperation with our CFO Anni Acs, who excellently handled the business transition into the stock market, shares issue, and daily financial controlling. Anni has moved to a new job challenge and we wish her all the best.


Panion's epilepsy product classified as MUMS in EU for dogs and cats

Panion Animal Health AB has received the European Medicines Agency's acceptance of the classification as MUMS (Minor Use Minor Species) for our epilepsy product for both dogs and cats. The request for classification was submitted to the Committee for Medicinal Products for Veterinary Use (CVMP) in the European Medicines Agency (EMA) earlier in 2017 and has now been successfully evaluated. 


Panion's epilepsy drug candidate shows positive initial results in a long-term study by CombiGene

Panion Animal Health AB develops a new epilepsy medicine for dogs based on CombiGene's drug vector CG01. Initial results from CombiGene's long-term study in rats was released yesterday in a message, which is highly relevant for Panion's development of the product for epilepsy in dogs.



Panion at EMA's SME InfoDay

Panion has an active status as SME (Small and Medium-sized Enterprise) - at the European Medicines Agency (EMA), which gives access to a number of benefits, information sources, and financial incentives. CEO Anja Holm attended the SME InfoDay on Friday 17 November at the EMA's offices where agency officials together with scientific and regulatory experts from the European Network presented developments and were ready to meet and discuss with companies on an informal basis.


2017 Q3 report, July-September for Panion Animal Health

Period July-September 

  • Net sales: kSEK 0 (0)
  • Operating profit: kSEK -923 (-43)
  • Earnings per share: SEK -0,25 (-0,01)
  • Liquidity at the end of the period: kSEK 1 166 (541)

Period January-Sept 

  • Net sales: kSEK 0 (0).
  • Operating profit: kSEK -3 501 (-43)
  • Earnings per share: SEK -0,25 (-0,01)
  • Liquidity at the end of the period: kSEK 1 166 (541)

Interview on gene therapy with board member Nerry Kamstrup

Interview on gene therapy with board member Nerry Kamstrup Once a year the World Small Animal Veterinary Association WSAVA hosts a congress for companion animal veterinarians from across the globe, and this year it was held in Copenhagen. The Danish Society of Veterinary Ophthalmology, DSVO, saw the opportunity to have the Nordic Eye Meeting hosted in Denmark in connection to the congress.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90
Kontaktformulär

Kontakta oss

Vill du veta mer om beQuoted och våra tjänster så fyll i nedanstånde uppgifter och tryck skicka.

En av våra rådgivare kontaktar dig inom kort.

Namn: Telefon: E-postadress: Meddelande: